ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Helix BioPharma Company (PK)

Helix BioPharma Company (PK) (HBPCF)

0.9143
0.00
(0.00%)
Closed September 19 4:00PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.9143
Bid
0.9143
Ask
0.9143
Volume
-
0.00 Day's Range 0.00
0.6885 52 Week Range 0.831
Market Cap
Previous Close
0.9143
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
850
Shares Outstanding
49,021,536
Dividend Yield
-
PE Ratio
-9.82
Earnings Per Share (EPS)
-0.13
Revenue
-
Net Profit
-6.29M

About Helix BioPharma Company (PK)

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Toronto, Ontario, Can
Founded
-
Helix BioPharma Company (PK) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker HBPCF. The last closing price for Helix BioPharma (PK) was $0.91. Over the last year, Helix BioPharma (PK) shares have traded in a share price range of $ 0.6885 to $ 0.831.

Helix BioPharma (PK) currently has 49,021,536 shares outstanding. The market capitalization of Helix BioPharma (PK) is $44.82 million. Helix BioPharma (PK) has a price to earnings ratio (PE ratio) of -9.82.

HBPCF Latest News

Helix Biopharma Corp. (HBPC: Grey Market) | Symbol Change

Tue, Apr 02, 2013 12:00 - Helix Biopharma Corp. (HBPC: Grey Market) - Symbol Change - The symbol, HBPC, is no longer a valid symbol for Helix Biopharma Corp.. As of Tue, Apr 02, 2013, the new...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120.083310.02406738870.8310.8310.77558500.80814706CS
260.174323.55405405410.740.8310.68859200.767472CS
520.207829.41259731070.70650.8310.68859160.75548799CS
156-1.8697-67.15876436782.7842.9810.688510201.25853717CS
260-3.6357-79.90549450554.555.74050.688516032.69590644CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GIPLGlobal Innovative Platforms Inc (CE)
$ 0.10
(9,999,900.00%)
605
ZHCLFZenith Capital Corporation (CE)
$ 0.07
(6,999,900.00%)
5.54k
AUSAFAustralis Capital Inc (CE)
$ 0.0101
(1,009,900.00%)
9.26k
ZAAGZA Group Inc (PK)
$ 0.0001
(9,900.00%)
512.76k
NWPNNow Corp (PK)
$ 0.0001
(9,900.00%)
5.76M
PFTIPuradyn Filter Technologies Inc (CE)
$ 0.000001
(-99.96%)
200k
GENNGenesis Healthcare Inc (CE)
$ 0.000001
(-99.91%)
2k
ATHXQAthersys Inc New (CE)
$ 0.000001
(-99.90%)
968
STIXFSemantix Inc (CE)
$ 0.0002
(-99.88%)
1.76k
GOSYGeckosystems International Corp (CE)
$ 0.000001
(-99.33%)
1M
AAPJAAP Inc (PK)
$ 0.0003
(-40.00%)
559.12M
AMLHAmerican Leisure Holdings Inc (PK)
$ 0.0003
(0.00%)
142.01M
ASIIAccredited Solutions Inc (PK)
$ 0.0006
(0.00%)
108.17M
HMBLHUMBL Inc (PK)
$ 0.00015
(50.00%)
100.64M
HCMCHealthier Choices Management Corporation (PK)
$ 0.000001
(-98.00%)
95.68M

HBPCF Discussion

View Posts
Renee Renee 1 month ago
HBPCF: effective Aug. 16,2024 a one for 5 reverse split:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes
👍️0
Renee Renee 11 years ago
HBPC changed to HBPCF:

http://www.otcbb.com/asp/dailylist_detail.asp?d=04/01/2013&mkt_ctg=NON-OTCBB
👍️0
Renee Renee 12 years ago
Helix BioPharma delisted from AMEX to OTC. Ticker change from HBP to HBPC.

http://www.otcbb.com/asp/dailylist_detail.asp?d=07/19/2012&mkt_ctg=NON-OTCBB
👍️0
mlkrborn mlkrborn 12 years ago
Helix BioPharma approves the selection of Director Robert Verhagen as CEO; plans to voluntarily delist from NYSE MKT (HBP) 1.40 : Co announces that its Board has approved the selection of Robert Verhagen as Chief Executive Officer. Verhagen is currently a Director for co. Co also announces that the Board has approved the voluntarily delisting of Helix's common shares from the NYSE MKT. The common shares will continue to trade on the Toronto Stock Exchange under the ticker symbol HBP and the co will continue to file the necessary reports with Canadian Securities.
👍️0
mlkrborn mlkrborn 12 years ago
Helix BioPharma provides update to shareholders; appoints William White as interim CEO on Thursday after the close (HBP) 1.75 : Co announces approved the initiation of Helix's planned Polish Phase I/II clinical trial of its lung cancer drug candidate L-DOS47 according to the approved protocol beginning with the monotherapy arm. The co currently plans to commence patient recruitment in this study before the end of its third fiscal quarter in April 2012, and will report on the expected schedule for this study when it is available. William White, Helix's Chairman of the Board, has been appointed as interim Chief Executive Officer to replace Donald Segal who has resigned as of the date of this announcement, as was previously anticipated. In this capacity, White will oversee the management, operations and financing strategies of the Company in the short term and immediately implement a search for a permanent CEO.
👍️0
mlkrborn mlkrborn 13 years ago
Helix BioPharma Corp. Announces Appointment of Special Committee
MarketwirePress Release: Helix BioPharma Corp. – 14 hours ago

Companies:

* Helix BioPharma Corp.
* HELIX BIOPHARMA
* Helix Biopharma Corp.

RELATED QUOTES
Symbol Price Change
HBP.TO 1.86 +0.16

AURORA, ON--(Marketwire -11/16/11)- Helix BioPharma Corp. (TSX: HBP.TO - News) (AMEX: HBP.TO - News) (Frankfurt: HBP.TO - News) ("HBP" or "the Company") announces that its Board of Directors (the "Board") appointed a special committee of independent directors (the "Special Committee") to advise the Board with respect to the Company's annual general meeting of shareholders to be held on January 30, 2012 (the "Meeting"). The members of the Special Committee are Jack M. Kay and W. Thomas Hodgson. The Special Committee is being advised by Norton Rose OR LLP.

The Special Committee will be dealing with matters recently raised by certain shareholders who participated in private placements by the Company in Europe. In this regard, a number of issues relating to the activities of third parties and their compliance with applicable laws have come to the attention of the Company's management and Board of Directors and have been referred to the Special Committee for further investigations.

Separately, the Company has retained Kingsdale Shareholder Services Inc. to assist with solicitation matters for the upcoming Meeting. A management information circular will be distributed to shareholders in advance of the Meeting.
👍️0
mlkrborn mlkrborn 13 years ago
HBP $1.96 Helix BioPharma: Clinical hold removed for co's Topical Interferon Alpha-2b Phase II/III efficacy trial IND application (HBP) 1.96 : Co announces that the "clinical hold" on its investigational new drug application for its Topical Interferon Alpha-2b, Phase II/III, low-grade cervical lesion efficacy trial has been removed by the FDA. The co is still in need of additional funding as well as strategic partner support before commencing this trial. As such, it does not currently have an estimated timeline for commencement or completion of this trial. The co hopes, however, that this FDA approval will be helpful in generating the support it requires
👍️0

Your Recent History

Delayed Upgrade Clock